Encaleret boosts bone turnover and improves symptoms in ADH1 patients, with FDA Priority Review underway.

BridgeBio Pharma announced that encaleret, a treatment for autosomal dominant hypocalcemia type 1 (ADH1), increased bone turnover and improved patient-reported symptoms in the Phase 3 CALIBRATE trial. 100% of patients on encaleret reported symptom improvements versus 46% on standard care, with better daily functioning outcomes. The FDA has accepted the NDA for encaleret with Priority Review and a decision expected by May 8, 2027. Additionally, the first patient was dosed in the RECLAIM-HP Phase 3 study for chronic hypoparathyroidism, aiming to further evaluate encaleret's efficacy and safety.

BridgeBio Pharma's stock is trading at USD 65.35 on Pluang, showing a modest 0.48% increase in the past day. The stock's market cap stands at $12.78 billion, with a 52-week range between $53.24 and $90.17. These figures are current as of Oct 11, 2026 23:11 WIB.